Amgen stops trial of Teneobio cancer candidate, taking $650M BiTE out of earnings

[cafead]

via Amgen’s Teneobio misadventure has taken a $650 million BiTE out of its earnings. The Big Biotech took the hit after stopping a phase 1 trial of the PSMA bispecific it picked up in the $900 million acquisition of Teneobio two years ago.

article source